ID: ALA608928

Max Phase: Preclinical

Molecular Formula: C20H24N5O9P

Molecular Weight: 509.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1ccn(C2O[C@H](COP(=O)(O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O)[C@@H](O)[C@H]2O)c(=O)n1

Standard InChI:  InChI=1S/C20H24N5O9P/c21-15-5-6-25(20(30)23-15)18-17(27)16(26)14(34-18)9-33-35(31,32)24-13(19(28)29)7-10-8-22-12-4-2-1-3-11(10)12/h1-6,8,13-14,16-18,22,26-27H,7,9H2,(H,28,29)(H2,21,23,30)(H2,24,31,32)/t13-,14+,16+,17+,18?/m0/s1

Standard InChI Key:  YEWNMHIPVFEZJQ-BGDHGMISSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 509.41

Molecular Weight (Monoisotopic): 509.1312

AlogP: -0.67

#Rotatable Bonds: 9

Polar Surface Area: 222.25

Molecular Species: ACID

HBA: 10

HBD: 7

#RO5 Violations: 2

HBA (Lipinski): 14

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 2.45

CX Basic pKa:

CX LogP: -1.47

CX LogD: -7.10

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.18

Np Likeness Score: 0.88

References

1. Whalen LJ, McEvoy KA, Halcomb RL..  (2003)  Synthesis and evaluation of phosphoramidate amino acid-based inhibitors of sialyltransferases.,  13  (2): [PMID:12482445] [10.1016/s0960-894x(02)00735-7]

Source

Source(1):

• Scientific Literature